Skip to main content
OpenTrials
Completed

NCT Number: NCT04929470

Safety and Performance of Ultra/Ultra 3D Cl With HiFocus SlimJ Electrode in Adults With Severe-to-profound Hearing Loss

This is a prospective study designed to evaluate the safety and performance of the HiResTM Ultra Cl HiFocusTM SlimJ Electrode and HiResTM Ultra 3D Cl HiFocusTM SlimJ Electrode (Ultra X) under normal conditions of use as it is approved for this device. Participants receive interventions as part of routine medical care.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

HNO-Klinik Düsseldorf, Düsseldorf, Germany

Loading trial locations.

About this study

This study is set up to document any adverse events and comparing pre- to post-implant benefit to subjects. Any adverse events associated with the device will be documented via Advanced Bionics complaint handling system for the lifetime of the device. A within-subjects repeated-measures design will be employed. Speech perception will be evaluated preoperatively with conventional amplification to determine candidacy and to establish baseline performance. Efficacy parameters are speech perception data which will be collected according to clinical routine with a 6 month follow up period. Subjects will be implanted unilaterally with the Ultra X according to standard clinical care.

The primary efficacy objective is to demonstrate that mean monosyllabic word recognition score with the Ultra X used in combination with a sound processor programmed with the latest fitting software six months after activation is at least 20% better than the mean word score at baseline with conventional amplification in the same ear.

The primary efficacy endpoint is reached six months after device activation.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No previous experience with any auditory implant
  • 18 years of age or older
  • Postlingual onset of severe hearing loss (≥ 4 years of age)
  • Limited benefit from appropriately fitted hearing aids, defined as scoring 60% or less in Freiburger Monosyllabic word test
  • German language proficiency
  • Willingness to participate in all scheduled procedures outlined in the protocol

Exclusion criteria

  • Cochlear malformation or obstruction that would preclude full insertion of electrode array.
  • Presence of additional disabilities that would prevent or interfere with participation in the required study procedures
  • Medical or psychological conditions that contraindicate surgery or impact the ability to manage an implanted device or the study related procedures
  • Evidence of central auditory lesion or compromised auditory nerve
  • Pregnancy at time of surgery.

Treatment and study plan

Cochlear implantation

Device

patients receive a cochlear implantation within clinical routine

Primary outcomes

  1. Freiburger Monosyllables Score in Quiet

    Time frame: 6 months

    score in % correct (scale from 0 to 100% of correct answers)

Secondary outcomes

  1. Speech Reception Theshold (SRT) in Noise

    Time frame: 6 months

    50 % SRT in the Oldenburger Sentence Test (OlSa) in noise. Results expressed in dB Signal-Noise-Ratio (SNR)

Sponsors and collaborators

Lead sponsor

Advanced Bionics AG

Industry

Registry information

Official study title

Clinical Investigation of the Safety and Performance of HiResTM Ultra Cl HiFocusTM SlimJ Electrode (Cl-1600-05) and HiResTM Ultra 3D Cl HiFocusTM SlimJ Electrode (Cl-1601-05) (Ultra X) in Adults With Severe-to-profound Hearing Loss

Important dates

Study start
2021
Primary completion
2026
Study completion
2026
First posted
Jun 18, 2021
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.